Abstract 2 Results of an Open Label Expanded Access Study of Omidubicel-onlv for Allogeneic Transplantation (allo-HCT) in Patients with Hematologic Malignancies

INTRODUCTION: Omidubicel, a nicotinamide expanded allogeneic hematopoietic progenitor cell therapy derived from umbilical cord blood (UCB) was recently FDA approved for use as a sole donor source in allo-HCT based on phase III study results showing improved hematopoietic recovery and decreased infec...

Descripción completa

Detalles Bibliográficos
Autores principales: Horwitz, Mitchell, Schiller, Gary, Tsai, Stephanie, Rezvani, Andrew, Maziarz, Richard, Goshen, Uri, Levy, Stuart, Schwarzbach, Aurelie, Mazor, Roei, Stiff, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Clinical Trials – Hematopoietic Stem Cell Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476934/
http://dx.doi.org/10.1093/stcltm/szad047.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476934/
http://dx.doi.org/10.1093/stcltm/szad047.003

Ejemplares similares